Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.

228.97 2.53 −1.09%
Market cap
$162.7B
P/E
40.5×
Fwd P/E
29.2×
Dividend yield
0.66%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

6.84% 7.08% 7.11% 7.63%
Piotroski F-Score
7 6 6 6
ROA
4.36% 4.49% 4.54% 4.60%
ROIC
4.34% 4.42% 4.59% 4.37%
Return on Tangible Assets
40.46% 31.48% 30.89% 36.07%
Average Days of Receivables
56.48 58.13 56.26 57.64
Free Cash Flow per Share
7.07 7.43 7.51 7.78
Free Cash Flow
5,028.00 5,293.00 5,318.00 5,489.00
Capital Expenditures
(1,290.00) (1,123.00) (1,121.00) (1,146.00)
Other line items
Cash ROIC
7.24% 7.00% 6.98% 6.69%
Accounts Receivable Turnover
6.68 6.60 6.77 6.67
Accounts Payable Turnover
5.96 5.59 5.79 5.87
Inventory Turnover
3.67 4.17 3.96 3.50
Average Days of Payables
63.11 67.00 64.21 63.85
Days of Inventory on Hand
99.38 90.44 93.55 114.24
Tax Rate
(0.16) (0.15) (0.15) (0.16)
Research and Development Expense of Revenue
6.60% 6.50% 6.48% 6.43%
Selling, General and Administrative Expense of Revenue
33.92% 33.52% 33.24% 31.66%
Share Based Compensation of Revenue
1.20% 1.21% 1.19% 1.18%
Interest Coverage
17.02 17.70 18.59 17.56
Operating CF/Net income
1.80 1.78 1.75 1.66
Depreciation/Fixed assets
0.45 0.44 0.45 0.44
Capex/Depreciation
(0.53) (0.46) (0.45) (0.44)
Revenue per Share
34.15 34.47 35.00 35.60
Operating CF per Share
8.89 9.00 9.10 9.41
Capex per Share
(1.82) (1.58) (1.58) (1.62)
Capex to Sales
0.05 0.05 0.05 0.05

Fold the line items

Columns are period end dates